**Supplementary table S1:** Serum cytokine levels in UUO model (day 10)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| cytokine[pg/ml] | SHAM | placebo | finerenone10 mg/kg | empagliflozin30 mg/kg |
| IL-12 (p40) | 65.6 ± 4.7\*\*\*\* | 137.8 ± 26.1 | 141.1 ± 25.6 | 127.8 ± 31.4 |
| Eotaxin | 434.0 ± 102.3 | 416.1 ± 80.1 | 400.0 ± 119.1 | 421.4 ± 95.3 |
| G-CSF | 144.1 ± 41.3 | 152.5 ± 36.4 | 144.1 ± 29.4 | 142.6 ± 20.3 |
| IL-17 | 7.8 ± 3.1 | 8.4 ± 4.6 | 8.8 ± 5.2 | 11.8 ± 3.7 |
| KC | 8.8 ± 1.8\*\* | 25.5 ± 7.2 | 30.5 ± 4.2 | 38.6 ± 11.4 |
| MCP-1 | 25.7 ± 2.3\*\* | 38.4 ± 4.7 | 36.7 ± 9.5 | 39.0 ± 8.4 |
| MIP-1β | 14.5 ± 4.0 | 16.3 ± 3.6 | 16.4 ± 2.7 | 16.2 ± 5.4 |
| RANTES | 24.9 ± 3.2 | 41.5 ± 7.5 | 39.2 ± 13.7 | 45.7 ± 18.3 |
| *Serum cytokine levels were assessed using the BioRad Pro Mouse cytokine-23 plex assay according to the manufacturer's protocol. SHAM n = 6, all other groups n = 12; data are expressed as means ± SD. Differences between placebo group were analyzed by one-way ANOVA with Dunnett’s corrections for multiple comparisons. Statistical significance was defined as p ≤ 0.05.* *Abbreviations:* *IL-12 (p40) = interleukin-12 subunit p40; Eotaxin/CCL11= chemokine (C-C Motif) ligand 11; G-CSF = granulocyte-colony stimulating factor; IL-17 = interleukin-17; KC =* *keratinocyte chemoattractant; MCP-1 = monocyte chemoattractant protein-1; MIP-1β = macrophage inflammatory protein 1 beta; RANTES = regulated and normal T cell expressed and secreted* |